Please login to the form below

Not currently logged in
Email:
Password:

Cyramza

This page shows the latest Cyramza news and features for those working in and with pharma, biotech and healthcare.

Lilly buys Armo for $1.6bn to bolster immuno-oncology pipeline

It also sells gastrointestinal cancer antibodies Erbitux (cetuximab) and recently launched Cyramza (ramucirumab).

Latest news

  • Baricitinib delay casts a pall over Lilly's results update Baricitinib delay casts a pall over Lilly's results update

    reliance on older products such as Trulicity (dulaglutide) for diabetes and cancer drug Cyramza (ramucirumab). ... Despite healthy growth - respectively 139% to $480m and 27% to $186m - in the second quarter, Trulicity and Cyramza are facing increasing

  • Lilly pitches Cyramza at bladder cancer Lilly pitches Cyramza at bladder cancer

    Lilly pitches Cyramza at bladder cancer. Pharma firm is now armed with phase III data from its RANGE study. ... Eli Lilly's Cyramza took a big step toward joining immuno-oncology agents as go-to therapies for bladder cancer, after improving

  • Lilly promises solanezumab news in Alzheimer's 'before year-end' Lilly promises solanezumab news in Alzheimer's 'before year-end'

    Among these, diabetes drugs Trulicity (dulaglutide) and Jardiance (empagliflozin) both saw solid sales gains that did not however meet analysts' expectations, while lung cancer therapy Cyramza (ramucirumab) fell 12% thanks to

  • Lilly snags first approval for sarcoma drug Lartruvo Lilly snags first approval for sarcoma drug Lartruvo

    Lilly still has patent protection for the blockbuster in the US until 2022, and in the meantime needs Lartruvo and other recent launches such as Cyramza (ramucirumab) and Portrazza (necitumumab) to

  • Lilly planning 20 new launches by 2023 Lilly planning 20 new launches by 2023

    Lechleiter noted that Lilly has launched six new products in the last two years alone - including Cyramza (ramucirumab), diabetes therapies Jardiance (empagliflozin) and Trulicity (dulaglutide) and most recently Taltz (ixekizumab) for

More from news
Approximately 10 fully matching, plus 14 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics